Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...

Cigna said that Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, have made repeated and incorrect ...

Expectations for both companies are really high. Morningstar estimates the GLP-1 drug market will be worth $200bn by 2031, and analysts expect Eli Lilly and Novo Nordisk to take the lion’s share of it ...

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

A little over a year ago, I took the stage at Livewire Live and made a 'shocking prediction' for 2024: we would witness “the ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

Shares in WeightWatchers surged by nearly 38% in extended hours trading on Wednesday, pointing to an extension in sharp gians ...

The average premium paid by companies for family coverage rose 7% for a second year in 2024, to $25,572 — without yet ...

With three large grants, the Department of Psychology, UCPH, and the National Institute of Public Health at SDU are ...

Medicare’s costs could balloon by the low to middle tens of billions of dollars over 10 years due to the cost of covering GLP-1 drugs for obesity.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...